NEWARK, Del., October 9, 2026. — The global hepatic sarcopenia nutrition market is estimated at USD 142.2 million in 2026 and is projected to reach USD 342.8 million by 2036, expanding at a CAGR of 9.2% from 2026 to 2036, according to Future Market Insights (FMI). The market stood at USD 130.2 million in 2025.

The growth outlook is being shaped by increasing demand for specialized nutrition that helps address inadequate protein intake among patients with liver disease and muscle loss. Poor appetite and early satiety can make it difficult for patients to consume sufficient nutrition through regular meals. FMI identifies high-protein oral nutritional supplements (ONS), branched-chain amino acid (BCAA)-enriched formulations and compact serving formats as important approaches to supporting nutritional intake.

Clinical nutrition guidance strengthens demand for specialized formulations

Nutritional management is becoming an important consideration in addressing muscle loss associated with chronic liver disease. The American College of Gastroenterology's May 2025 guideline recommends adequate protein intake, late-evening carbohydrate consumption and plant-based or BCAA-enriched protein sources for appropriate patients. FMI indicates that these recommendations support interest in specialized nutritional products designed to provide concentrated protein and liver-relevant amino acids in manageable servings.

👉 Get Detailed Market Forecasts, Competitive Benchmarking & Pricing Trends: https://www.futuremarketinsights.com/reports/sample/rep-gb-35744

What is driving demand for hepatic sarcopenia nutrition?

·         BCAA-enriched high-protein ONS — 41.5% share in 2026: Higher protein density and liver-relevant amino acids support the leading formulation position, particularly for patients who struggle to meet nutritional requirements through regular meals.

·         Compact serving formats: Smaller-volume nutritional products can help patients with poor appetite or early satiety consume additional protein without relying on large meals.

·         Late-evening nutrition: Nutritional strategies that include late-evening intake are supporting interest in products that fit structured dietary routines.

·         Continued nutritional support after discharge: Ongoing nutrition needs can create opportunities for products that patients can use at home following hospital treatment.

·         Evidence-based product selection: Clinical guidance, appropriate nutritional composition and clear instructions can influence product adoption among healthcare professionals and caregivers.

The hurdle

Maintaining consistent nutritional intake remains a central challenge. Patients experiencing poor appetite, early satiety or difficulty completing larger servings may struggle to meet their nutritional needs. FMI highlights the importance of compact formulations, appropriate protein composition and practical home-use instructions. For manufacturers, products that combine suitable nutritional profiles with manageable serving sizes and clear directions may be better positioned to support continued use.

For full coverage of the Hepatic Sarcopenia Nutrition Market, including market forecasts, formulation trends, competitive analysis and growth opportunities, visit the FMI report: https://www.futuremarketinsights.com/reports/hepatic-sarcopenia-nutrition-market

Recent developments

The market is seeing product launches and clinical nutrition initiatives focused on improving nutritional delivery, supporting structured care and making repeated supplementation more practical:

·         2026: Abbott maintained institutional ordering information for Ensure Plus High Protein, supporting access through hospitals and potential replenishment through retail or online channels.

·         January 2026: The Japan Association of Rehabilitation Nutrition highlighted the publication of the 2025 nutritional management guideline for sarcopenia and frailty, strengthening the evidence environment for structured nutritional care.

·         October 2025: Danone Nutricia launched Fortimel PlantBased Protein with savory options for disease-related malnutrition, addressing flavor fatigue associated with repeated oral nutrition.

·         March 2025: Medtrition launched its ProSource Cup portfolio, providing 20 grams of protein in a low-volume cup for oral or tube-fed use, supporting patients who have difficulty finishing larger servings.

FMI profiles companies across liver-specific amino-acid nutrition, broad medical nutrition platforms and compact clinical nutrition solutions. Key players include Otsuka Pharmaceutical and Ajinomoto in liver-specific amino-acid nutrition; Abbott, Nestlé Health Science and Danone Nutricia in medical nutrition; and Meiji Holdings, Fresenius Kabi and Medtrition in compact and modular clinical nutrition.

Analyst perspective

“In my experience, demand is moving towards smaller nutrition servings that patients can complete without disturbing the normal meal routine. Liver-relevant evidence and simple home instructions will decide which products continue regularly after hospital discharge.” — Nandini Roy Choudhury, Principal Consultant, Future Market Insights.

What this means for medical nutrition manufacturers and healthcare providers

·         Prioritize compact, protein-dense formulations. Products designed to deliver concentrated nutrition in smaller servings may help address challenges associated with poor appetite and early satiety.

·         Align product development with clinical nutrition guidance. Appropriate protein composition, BCAA-enriched options and consideration of late-evening nutritional intake can help manufacturers address specific nutritional care requirements.

·         Support continuity of care after discharge. Clear home-use instructions, convenient serving formats and reliable product access can help patients and caregivers incorporate nutritional supplementation into ongoing care.

·         Address flavor fatigue and ease of consumption. Product variety and practical formats may support acceptance when oral nutritional supplements are used repeatedly.

Related Reports:

Calcium Gluconate Market https://www.futuremarketinsights.com/reports/calcium-gluconate-market

Inositol Market https://www.futuremarketinsights.com/reports/inositol-market

Macadamia Market https://www.futuremarketinsights.com/reports/macadamia-market

Edible Nuts Market https://www.futuremarketinsights.com/reports/edible-nuts-market

Foodservice Equipment Market https://www.futuremarketinsights.com/reports/foodservice-equipment-market

About Future Market Insights

Future Market Insights, Inc. (FMI) is an ESOMAR-certified market research and consulting firm headquartered in Delaware, USA, with offices in the United Kingdom, the United Arab Emirates and India. FMI delivers syndicated and custom research across food and beverage, healthcare, chemicals, technology, packaging, consumer goods and industrial sectors.

For Press & Corporate Inquiries

Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075

For Sales: sales@futuremarketinsights.com

For Media: Rahul.singh@futuremarketinsights.com

For Web: https://www.futuremarketinsights.com/